Skip to content
OpenCapital
Get started

4D Molecular Therapeutics FDMT Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
EyePoint, Inc. logo
EyePoint, Inc. EYPT
$1.02B+228%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
Regenxbio logo
RegenxbioRGNX
$488.35M+58.6%

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$602.22M+215%
P/S6.8×-8,306×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0×0.0×
Current ratio9.3×-3.0×

Where this comes from

Calculated from 4D Molecular Therapeutics’s reported figures.

$475.3Mmarket cap+$20.5Mtotal debt−$72.5Mcash and equivalents=$423.34M

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 4D Molecular Therapeutics's enterprise value?
4D Molecular Therapeutics (FDMT) reported enterprise value of $423.34M in Q1 2026.
How has 4D Molecular Therapeutics's enterprise value changed year-over-year?
4D Molecular Therapeutics's enterprise value increased by 961.4% year-over-year, from $39.88M to $423.34M.
What is the long-term trend for 4D Molecular Therapeutics's enterprise value?
Over 5 years (2020 to 2025), 4D Molecular Therapeutics's enterprise value has grown at a -14.4% compound annual growth rate (CAGR), from $847.68M to $389.69M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.